You are here

Update on the NICE evaluation of ponatinib

Following the publication of the NICE Appraisal Consultation Document (ACD) NHS England (NHSE) have now updated the National Cancer Drugs Fund (CDF) List to include ponatinib treatment for both accelerated and blast phases. 

Doctors with patients in either of these two phases can now, should they and the patient consider it appropriate, apply to the CDF for reimbursement (payment by the NHS to the drug company, Incyte) for ponatinib treatment.

We should welcome this very prompt response by NHSE at a stage where the final NICE recommendation is as yet unknown although I think, after reading the ACD, its safe to assume that the NICE Committee will re-affirm their recommendation for both these phases.  

Doctors with patients with the T315i mutation can continue, as before, to apply to the CDF for reimbursement. 

Here is the NHSE website link: 

https://www.england.nhs.uk/wp-content/uploads/2017/02/national-cdf-list-...

Scroll down to page 13

 

Return to thread